


Please amend the following claims: ✓

2. (amended) A compound of the formula



wherein R_1 is H; alkyl; substituted alkyl; alkoxy; halo; substituted alkoxy; hydroxy; trifluoralkyl; nitro; amino; alkylamino; cycloalkylamino; cyano; carboxy; cycloalkyl; phenyl; and substituted phenyl;

R_2 is H; hydroxy; alkyl; substituted alkyl; halo; heterocycloalkyl; heteroaryl; phenyl; substituted phenyl; naphthyl and substituted naphthyl;

B_1 is hydrogen;

B_2 is hydrogen; or B_1 and B_2 are methylene and joined together to form a five or six membered ring;

Y is methylene or carbonyl;

Z is selected from the group consisting of aryl; substituted aryl; N-sulfonamido; N-(aryl)sulfonamido; substituted N-(aryl)sulfonamido; arylamido; substituted arylamido; arylureido; substituted arylureido; arylacetamido; substituted arylacetamido; (aryloxy)carbonylamino; substituted (aryloxy)carbonylamino; 2,3-dihydro-2-oxo-1H-benzimidazol-1-yl; substituted 2,3-dihydro-2-oxo-1H-benzimidazol-1-yl; 1-aryl-2,3-dihydro-4-oxo-imidazol-5,5-diyl; and substituted 1-aryl-2,3-dihydro-4-oxo-imidazol-5,5-diyl;

contd.
a¹

L is C₁₋₆alkylene; C₂₋₁₀ alkenylene; C₂₋₁₀ alkynylene; C₃₋₇cycloalkylene;
C₃₋₇cycloalkylC₁₋₄alkylene; arylC₁₋₄ alkylene; α -aminoC₄₋₇alkylene;
(N-methylene)piperidin-4-yl; substituted (N-methylene)piperidin-4-yl;
(N-methylene)piperazin-4-yl; (N-methylene)pyrrolidin-3-yl; (N-methylene)-4-acetyl-
piperidin-4-yl; and (N-methylene)piperidin-4,4-diyl;

n is 1-2;

m is 1-3;






p is 1-3; and

q is 1-3.

2020-01-20

contd.
a¹







3. (amended) A compound of claim 2 selected from the group consisting of:



and

contd.
a¹







4. (amended) A compound of claim 2 selected from the group consisting of:



and






contd.
a¹

5. (amended) A compound of claim 2 selected from the group consisting of:



and






8. (amended) A compound of claim 2 selected from the group consisting of:



and

contd
a²


9. (amended) A compound of claim 2 selected from the group consisting of:



and

3

12. (amended) A compound of claim 2 selected from the group consisting of:



and

Please add the following new claims: ✓

17. A method of treating disorders and diseases associated with NPY receptor subtype 5 comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of claim 2.

18. A pharmaceutical composition for the treatment of diseases or disorders associated with the NPY Y5 receptor subtype comprising a therapeutically effective amount of a compound of claim 2 and a pharmaceutically acceptable carrier.

19. A pharmaceutical composition according to claim 18 for the treatment of disorders or disease states caused by eating disorders, obesity, bulimia nervosa, diabetes, memory loss, epileptic seizures, migraine, sleep disturbances, pain, sexual/reproductive disorders, depression and anxiety.